The life sciences investment landscape: innovation in a time of scarcity
June 2nd 2025
Life sciences investment is at a crossroads.
While some “green shoots” are visible, the broader environment remains cautious of life sciences investment. Venture capital is tight, IPO activity is subdued, and private equity is hesitant yet hopeful.
During a recent CCO round table, participants shared a recurring theme: it’s easier right now to raise a massive new fund than to secure a few million pounds for a promising project. This paradox reflects the psychological uncertainty that has gripped early-stage biotech, medtech, and their investors.
“It’s easier right now to raise a massive new fund than to secure a few million pounds for a promising project.”
Big pharma is not expected to be the white knight. Although major players are cash-rich, they’re choosing safe bets like commodities and hedging over riskier co-development ventures. That said, partnerships between pharma and smaller biotech firms remain a key part of the innovation ecosystem.
Reduced interest rates in markets like the U.S. may eventually stimulate more risk-taking, but until then, companies are being forced to operate leaner and smarter. In this climate, innovation must be tightly aligned with return on investment, and strong data storytelling is essential to secure funding.
Are you seeking a trusted partner to support your executive search in Life Sciences?
We bring decades of executive search experience and a proven track record of success across our dedicated sectors. Our investor clients rely on us time and again to build exceptional leadership teams that drive growth and deliver results.
